Your browser doesn't support javascript.
loading
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade.
Hooper, Andrea T; Marquette, Kimberly; Chang, Chao-Pei Betty; Golas, Jonathon; Jain, Sadhana; Lam, My-Hanh; Guffroy, Magali; Leal, Mauricio; Falahatpisheh, Hadi; Mathur, Divya; Chen, Ting; Kelleher, Kerry; Khandke, Kiran; Muszynska, Elwira; Loganzo, Frank; Rosfjord, Edward; Lucas, Judy; Kan, Zhengyan; Subramanyam, Chakrapani; O'Donnell, Christopher; Neri, Dario; Gerber, Hans-Peter; May, Chad; Sapra, Puja.
Affiliation
  • Hooper AT; Pfizer Worldwide Research, Development & Medicine, Oncology Research & Development, Pearl River, New York.
  • Marquette K; Pfizer Worldwide Research, Development & Medicine, BioMedicine Design, Cambridge, Massachusetts.
  • Chang CB; Pfizer Worldwide Research, Development & Medicine, Oncology Research & Development, Pearl River, New York.
  • Golas J; Pfizer Worldwide Research, Development & Medicine, Oncology Research & Development, Pearl River, New York.
  • Jain S; Pfizer Worldwide Research, Development & Medicine, BioMedicine Design, Cambridge, Massachusetts.
  • Lam MH; Pfizer Worldwide Research, Development & Medicine, Oncology Research & Development, Pearl River, New York.
  • Guffroy M; Pfizer Worldwide Research, Development & Medicine, Drug Safety Research & Development, Pearl River, New York.
  • Leal M; Pfizer Worldwide Research, Development & Medicine, BioMedicine Design, Cambridge, Massachusetts.
  • Falahatpisheh H; Pfizer Worldwide Research, Development & Medicine, Drug Safety Research & Development, Pearl River, New York.
  • Mathur D; Pfizer Worldwide Research, Development & Medicine, Oncology Research & Development, Pearl River, New York.
  • Chen T; Pfizer Worldwide Research, Development & Medicine, BioMedicine Design, Cambridge, Massachusetts.
  • Kelleher K; Pfizer Worldwide Research, Development & Medicine, BioMedicine Design, Cambridge, Massachusetts.
  • Khandke K; Pfizer Worldwide Research, Development & Medicine, Oncology Research & Development, Pearl River, New York.
  • Muszynska E; Pfizer Worldwide Research, Development & Medicine, Oncology Research & Development, Pearl River, New York.
  • Loganzo F; Pfizer Worldwide Research, Development & Medicine, Oncology Research & Development, Pearl River, New York.
  • Rosfjord E; Pfizer Worldwide Research, Development & Medicine, Oncology Research & Development, Pearl River, New York.
  • Lucas J; Pfizer Worldwide Research, Development & Medicine, Oncology Research & Development, Pearl River, New York.
  • Kan Z; Pfizer Worldwide Research, Development & Medicine, Oncology Research & Development, Pearl River, New York.
  • Subramanyam C; Pfizer Worldwide Medicinal Chemistry, Groton, Connecticut.
  • O'Donnell C; Pfizer Worldwide Medicinal Chemistry, Groton, Connecticut.
  • Neri D; Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
  • Gerber HP; Pfizer Worldwide Research, Development & Medicine, Oncology Research & Development, Pearl River, New York.
  • May C; Pfizer Worldwide Research, Development & Medicine, Oncology Research & Development, Pearl River, New York.
  • Sapra P; Pfizer Worldwide Research, Development & Medicine, Oncology Research & Development, Pearl River, New York.
Mol Cancer Ther ; 21(9): 1462-1472, 2022 09 06.
Article de En | MEDLINE | ID: mdl-35793468

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Immunoconjugués Limites: Animals / Female / Humans Langue: En Journal: Mol Cancer Ther Sujet du journal: ANTINEOPLASICOS Année: 2022 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Immunoconjugués Limites: Animals / Female / Humans Langue: En Journal: Mol Cancer Ther Sujet du journal: ANTINEOPLASICOS Année: 2022 Type de document: Article